Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Exelixis initiates a phase 3 trial with cabozantinib combination for previously untreated liver cancer

December 6, 2018 0

Exelixis (EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) versus sorafenib, in previously untreated advanced hepatocellular carcinoma (HCC). The co-primary endpoints of the trial are: progression-free survival and overall survival. An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting. COSMIC-312 is a multicenter, randomized, controlled …

Celgene has important CAR T presentations at ASH

Vertex: Offering proof of leadership in treating Cystic Fibrosis

Loxo Oncology product Vitrakvi® has been granted FDA approval. The...

What the Aimmune and Nestlé Health Science agreement tells us

Jazz Pharmaceuticals has good, not bad news

RegenxBio: Another licensing agreement providing additional validation of its NAV...

About Illumina’s acquisition

Observing Array Biopharma

Alleviating osteoarthritis pain without the need for opioid drugs

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched...

$Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients$

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated...

The FDA granted Paratek two important product approvals. One is...

Antisense investigational product demonstrates successful results treating a life-threatening disease...

The medical news of the year comes at the hands...

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver...

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

Gilead Sciences: In pursuit of cures for intractable diseases

Amgen and AstraZeneca have in hand a very much needed...

Today’s Highlights

There are no reasons for the Market’s tumbling. The value of the Biotech Revolution.

December 7, 2018 0

Today, the market took another beating as a result of either an intentional or an unintentional …

$Amgen and UCB product for bone fracture in susceptible postmenopausal women. What about the Market’s deep dips?$

Amgen and UCB product for bone fracture in susceptible postmenopausal women. What about the Market’s deep dips?

December 6, 2018 0

Another reason was found to hit the market when the economy is good and sustained and …

Why Celyad stock lost today instead of gaining on good news

November 30, 2018 0

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, …

RegenxBio attracts more companies. Why Loxo is important to observe today

November 26, 2018 0

We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did. …

A great day for Exelixis

November 15, 2018 0

This is just to inform that Europe has approved Cabometyx® (cabozantinib) tablets as a monotherapy for hepatocellular …

Excellent news about little known products and Nektar Therapeutics

November 12, 2018 0

The Week in Review, which we will post soon, is going to provide news that cancer …

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

November 8, 2018 0

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we …

About Exelixis

November 2, 2018 0

Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved …

About the Celyad/Horizon discovery agreement

November 1, 2018 0

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA …

Prenatal gene editing has already been performed in laboratory animals

October 26, 2018 0

Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing …

The Week in Review

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Prohost Letters

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

Revisiting Biotech Companies We Highlighted

May 25, 2018 0

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

Private Lessons and More

February 9, 2018 0

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …

The Year in Review Part 2

January 10, 2018 0

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …